.

Pharmaceutical Business Intelligence

  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Aspirin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for aspirin?

Aspirin is the generic ingredient in fifty-three branded drugs marketed by Bayer, New Haven Pharms, Plx Pharma, Savage Labs, Actavis Elizabeth, Watson Labs, Allergan Sales Llc, Ivax Pharms, Halsey, Puracap Pharm, Nostrum Labs Inc, Hikma Intl Pharms, Quantum Pharmics, Lannett, Pharmaceutics Intl, Sandoz, Nexgen Pharma Inc, Mayne Pharma Inc, Stevens J, Vintage Pharms Llc, Sun Pharm Inds, Medicis, Prinston Inc, Teva, Alra, Ivax Sub Teva Pharms, Xanodyne Pharm, Ingenus Pharms Nj, Oxford Pharms, Meda Pharms, Heritage Pharms Inc, Barr, Sandoz Inc, Par Pharm Inc, Impax Labs Inc, Boehringer Ingelheim, Amneal Pharms, Schwarz Pharma, Abbott, Caraco, Par Pharm, Medpointe Pharm Hlc, Robins Ah, Mcneil, Aralez Pharms, Endo Pharms, Actavis Labs Fl Inc, Roxane, Sanofi Aventis Us, Bristol Myers Squibb, and Aaipharma Llc, and is included in eighty NDAs. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aspirin has twenty-eight patent family members in eighteen countries.

There are twenty-one drug master file entries for aspirin. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: aspirin

Tradenames:53
Patents:11
Applicants:51
NDAs:80
Drug Master File Entries: see list21
Suppliers / Packagers: see list1
Bulk Api Vendors: see list73
Clinical Trials: see list499
Patent Applications: see list141,253
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:aspirin at DailyMed

Tentative approvals for ASPIRIN

Applicant Application No. Form Dosage
► Subscribe► SubscribeCAPSULE, EXTENDED RELEASE;ORAL25MG;200MG
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaipharma Llc
DARVON-N W/ ASA
aspirin; propoxyphene napsylate
TABLET;ORAL016863-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Medpointe Pharm Hlc
MICRAININ
aspirin; meprobamate
TABLET;ORAL084978-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
Sanofi Aventis Us
TALWIN COMPOUND
aspirin; pentazocine hydrochloride
TABLET;ORAL016891-001Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe
Hikma Intl Pharms
BUTALBITAL, ASPIRIN AND CAFFEINE
aspirin; butalbital; caffeine
TABLET;ORAL086162-002Feb 16, 1984RXNoYes► Subscribe► Subscribe
Oxford Pharms
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE
aspirin; carisoprodol; codeine phosphate
TABLET;ORAL040283-001Dec 29, 1998DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: aspirin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,911,752Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: aspirin

Country Document Number Estimated Expiration
MexicoPA03005550► Subscribe
South Korea20140105436► Subscribe
European Patent Office1343529► Subscribe
Denmark1343529► Subscribe
Australia2001297778► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ASPIRIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/048Ireland► SubscribePRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc